Metabolic support with perhexiline for myocardium protection in patients undergoing coronary artery surgery.

Status: Completed

Phase of Trial: Phase II/III

Latest Information Update: 09 Nov 2021

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Perhexiline (Primary)
Indications Myocardial ischaemia; Myocardial reperfusion injury
Focus Therapeutic Use
Acronyms CASPER

Most Recent Events

16 Sep 2015 Subgroup results (stereoselective handling of perhexiline) published in the European Journal of Clinical Pharmacology.
16 Nov 2011 Results presented at the 84th Annual Scientific Sessions of the American Heart Association.
20 May 2010 Planned end date changed from 29 Jan 2010 to 13 Apr 2010 as reported by United Kingdom Clinical Research Network record.

Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

IP authentication when working within your organization’s network.
Login with username/password or try access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days.
Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

Contact your organization’s admin about adding this content to your AdisInsight subscription
Buy a PDF version of the profile.
Request a free trial

Welcome to AdisInsight